SOLEY
LIVE

Serial Number

99624878

Owner

Soley Therapeutics, Inc.

Attorney

Alyssa M. Worsham

Filing Date

Jan 30, 2026

Add to watchlist:

No watchlists yet
View on USPTO

SOLEY Trademark

Serial Number: 99624878

SOLEY is a trademark filed by Soley Therapeutics, Inc. on January 30, 2026. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Soley Therapeutics, Inc. (6 trademarks)

1 Corporate Drive
South San Francisco, CA 94080

Entity Type: 03

Trademark Details

Filing Date

January 30, 2026

Registration Date

Not Registered

Goods & Services

Biological, medicinal and pharmaceutical preparations for the treatment of viral, infectious, metabolic, endocrine, musculoskeletal, autoimmune, cardiovascular, neuromuscular, central nervous system, rare muscle, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, genetic, blood, inflammatory, psychiatric, and immune system related diseases and disorders; therapeutic pharmaceuticals for the prevention and treatment of viral, infectious, metabolic, endocrine, musculoskeletal, autoimmune, cardiovascular, neuromuscular, central nervous system, rare muscle, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, genetic, blood, inflammatory, psychiatric, and immune system related diseases and disorders

Drug discovery services; pharmaceutical research and development services; providing online non-downloadable computer software for collecting, analyzing, reporting, and tracking data and information in the fields of genetics, genomics, phenomics, biology, chemistry, molecular biology, pathology, phenotypic sciences, omics, and image-based analysis; software as a service (SAAS) services featuring software for collecting, analyzing, reporting, and tracking data and information in the fields of genetics, genomics, phenomics, biology, chemistry, molecular biology, pathology, phenotypic sciences, omics, and image-based analysis; providing online non-downloadable computer software for use in generating, analyzing, and accessing data via advanced computational techniques, automation, infrastructure, artificial intelligence, and machine learning; software as a service (SAAS) services featuring software for use in generating, analyzing, and accessing data via advanced computational techniques, automation, infrastructure, artificial intelligence, and machine learning; providing an online non-downloadable computer software platform for discovering drugs, forecasting potential uses of drug compounds and generating insights from screening and analyzing molecules, featuring software using advanced computational techniques, automation, infrastructure, artificial intelligence, machine learning, computerized simulations, virtual screening, and generative chemistry; software as a service (SAAS) services featuring software for discovering drugs, forecasting potential uses of drug compounds and generating insights from screening and analyzing molecules, all using advanced computational techniques, automation, infrastructure, artificial intelligence, machine learning, computerized simulations, virtual screening, and generative chemistry; providing an online non-downloadable computer software platform for analyzing molecular data in the fields of genetics, genomics, phenomics, biology, chemistry, molecular biology, pathology, phenotypic sciences, omics, and image-based analysis for biotechnology and pharmaceutical companies; software as a service (SAAS) services featuring software for analyzing molecular data in the fields of genetics, genomics, phenomics, biology, chemistry, molecular biology, pathology, phenotypic sciences, omics, and image-based analysis for biotechnology and pharmaceutical companies; providing an online non-downloadable computer software platform for analyzing and generating insights from the sensing and response capabilities of cells; software as a service (SAAS) services featuring software for analyzing and generating insights from the sensing and response capabilities of cells; providing online non-downloadable computer software for decoding cellular language; software as a service (SAAS) services featuring software for decoding cellular language; providing online non-downloadable computer software for stain-free brightfield time-lapse imaging of cells; software as a service (SAAS) services featuring software for stain-free brightfield time-lapse imaging of cells; preclinical drug discovery services used for identifying, designing, and optimizing chemical compounds; pharmaceutical product evaluation and preclinical evaluation of chemical series and chemical compounds in drug discovery via software using artificial intelligence; preclinical pharmaceutical drug development services used for identifying, designing, and optimizing chemical compounds; pharmaceutical evaluation and preclinical evaluation of chemical series and chemical compounds in drug discovery; pharmaceutical drug development and discovery services, namely, identifying, designing, optimizing, and developing chemical series and chemical compounds via software using advanced computational techniques, automation, infrastructure, artificial intelligence, machine learning, computational modeling, high-throughput screening, medicinal chemistry, biology, pharmacology, computerized simulations, virtual screening, and generative chemistry; providing an online searchable database in the fields of pharmaceuticals for scientific research purposes, in particular, pharmaceutical research and development, scientific research and development of pharmaceutical preparations, scientific development of new uses for pharmaceutical compounds, and scientific technical research; scientific research and development for scientific purposes, namely, forecasting the use of molecules as drug compounds and developing new uses for pharmaceutical compounds; research and development in the field of drug discovery and development, molecular screening, cellular screening, phenomics, genetics, genomics, biology, chemistry, molecular biology, pathology, phenotypic sciences, omics, and image-based analysis; drug discovery services, namely, phenotypic screening services for discovering novel molecules to develop into drug compounds; medical and scientific research, namely, conducting clinical trials for others

Downloadable computer software for collecting, analyzing, reporting, and tracking data and information in the fields of genetics, genomics, phenomics, biology, chemistry, molecular biology, pathology, phenotypic sciences, omics, and image-based analysis; downloadable computer software, namely, software for use in generating, analyzing, and accessing data via advanced computational techniques, automation, infrastructure, artificial intelligence, and machine learning; downloadable computer software for discovering drugs, forecasting potential uses of drug compounds and generating insights from screening and analyzing molecules, all using advanced computational techniques, automation, infrastructure, artificial intelligence, machine learning, computerized simulations, virtual screening, and generative chemistry; downloadable computer software for analyzing molecular data in the fields of genetics, genomics, phenomics, biology, chemistry, molecular biology, pathology, phenotypic sciences, omics, and image-based analysis for biotechnology and pharmaceutical companies; downloadable computer software for analyzing and generating insights from the sensing and response capabilities of cells; downloadable computer software for decoding cellular language; downloadable computer software for stain-free brightfield time-lapse imaging of cells

Filing History

NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 2, 2026 GNRN
NON-FINAL ACTION E-MAILED
Jun 2, 2026 GNRT
NON-FINAL ACTION WRITTEN
Jun 2, 2026 CNRT
ASSIGNED TO EXAMINER
May 28, 2026 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
May 24, 2026 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 24, 2026 NWOS
APPLICATION FILING RECEIPT MAILED
Jan 30, 2026 MAFR
NEW APPLICATION ENTERED
Jan 30, 2026 NWAP